Takeda completes raft of settlements in US generic Actos litigation
This article was originally published in Scrip
Executive Summary
Takeda has now reached settlements with all of the defendants in patent infringement litigation that it had brought against filers of US ANDAs for generic versions of its big-selling oral antidiabetic, Actos (pioglitazone), and two combinations of this.